Skip to content

Study dataset

Endometrial Cancer (MSK, Clin. Cancer Research, 2018)

Prospective sequencing of advanced, mostly high-grade endometrial cancers.

Listed Apr 24, 2026

  • Genomic
  • Clinical
  • Endometrial

Overview

Cohort: Advanced-stage, predominantly high-grade endometrial cancers (recurrent or metastatic), distinct from the primary/untreated tumors in TCGA.

This dataset is notable for being a prospective, clinically-integrated sequencing cohort — making it particularly relevant for understanding treatment-refractory disease and actionable genomic alterations in advanced endometrial cancer.

Inside the dataset

  • MSK-IMPACT sequencing

    of 197 tumors from 189 patients — tumor-normal paired DNA sequencing using MSK's targeted panel, enabling somatic mutation calling, copy-number alteration profiling, and germline variant detection. cbioportal

  • Immunohistochemistry (IHC)

    for mismatch repair (MMR) protein expression, integrated with sequencing-based microsatellite instability (MSI) detection. cbioportal

  • Mutational signature analysis

    to identify MSI even in cases where standard MMR IHC failed. cbioportal

  • DNA copy-number alteration clustering

    to define genomic subgroups, identifying a novel subset with genome-wide heterozygous losses and significantly worse outcomes. cbioportal

  • Germline sequencing

    from matched normal DNA to detect pathogenic germline mutations. cbioportal

  • Clinical and treatment history data

    , including progression-free survival on first-line therapy and clinical trial enrollment and outcomes. cbioportal

Publications